Develops adoptive cell therapies and TCR-based therapies for cancer, focusing on targeting tumor-specific antigens for personalized treatments.
Immatics N.V., a leading clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, is dedicated to pioneering T cell receptor (TCR) based immunotherapies for the treatment of cancer. Operating primarily in the United States, Immatics focuses on developing targeted treatments for solid tumors using two innovative modalities: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine platform includes several promising product candidates currently in Phase I clinical trials. These include IMA201, which targets melanoma-associated antigen 4 or 8, IMA202 targeting melanoma-associated antigen 1, IMA203 focused on preferentially expressed antigen in melanoma, and IMA204, targeting tumor stroma cell, currently in preclinical studies.
In addition to its ACTengine platform, Immatics is advancing TCR Bispecifics product candidates through preclinical studies. These include IMA401, targeting a cancer testis antigen, and IMA402 for the treatment of various solid tumors. Immatics also develops IMA101 and IMA301, with the latter being an allogenic cellular therapy product candidate designed for cancer treatment. The company's strategic collaborations with GlaxoSmithKline Intellectual Property Development Limited, MD Anderson Cancer Center, Celgene Switzerland LLC, and Genmab A/S further enhance its capability to develop novel adoptive cell therapies and T cell engaging bispecific immunotherapies across multiple cancer indications.
Founded on a strong foundation of scientific innovation, Immatics N.V. continues to push the boundaries of cancer treatment research. With a commitment to leveraging TCR-based technologies and strategic partnerships, Immatics aims to deliver transformative therapies that address significant unmet medical needs, ultimately improving outcomes for cancer patients worldwide.